Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04331275 · ClinicalTrials.gov registry record · Phase 2
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
A Phase 2 study of Viral Infection and Solid Organ Transplant, sponsored by Children's Hospital Medical Center, Cincinnati.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04331275 is a Phase 2 study of Viral Infection and Solid Organ Transplant that is active but no longer recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 42 participants, below the 225-participant average among 11 other Viral Infection trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04331275, a Phase 2 study of Viral Infection and Solid Organ Transplant, is active but no longer recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to treat viral infections that may happen after solid organ transplant (SOT). VSTs are cells specially designed to fight viral infections that may happen after a solid organ transplant. These cells are created from a blood sample collected from the study participant. Solid organ transplant and the use of immunosuppressive medications reduces the body's ability to fight infections. Viral infections are a common problem after transplant and can cause significant complications. Reduction of immunosuppression may put the organ at risk of rejection. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study the investigators are trying to find a better way to treat these infections and minimize complications.
Conditions Studied
Interventions
- BIOLOGICAL Viral Specific T-cells (VSTs)
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04331275
The ClinicalTrials.gov registry entry for NCT04331275 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 11 other Viral Infection trials with a reported enrollment target (81% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Viral Infection appearing as the primary indexed condition, and to 1 intervention - of which Viral Specific T-cells (VSTs) is the first listed.
NCT04331275 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04331275 about?
NCT04331275 is a clinical study titled "Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant". The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to treat viral infections that may happen after solid organ transplant (SOT). VSTs are cells specially designed to fight viral infections that may happen after a solid organ transplant. These cel...
What is the current status of trial NCT04331275?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2020-08-18. Estimated completion is 2028-09.
What conditions does trial NCT04331275 study?
This clinical trial studies the following conditions: Viral Infection, Solid Organ Transplant.
What interventions are being tested in trial NCT04331275?
The interventions under investigation include: Viral Specific T-cells (VSTs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04331275?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04331275 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Third Party Viral Specific T-cells (VSTs)
RECRUITING · Phase 2
-
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
RECRUITING · Phase 2
-
Smell Changes & Efficacy of Nasal Theophylline
COMPLETED · Phase 2
-
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
RECRUITING · Phase 1
-
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
RECRUITING · Phase 1
-
School Inner City Air Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.